post top bottom beat continu see room signific upsid
vs consensu revenue/ep expect regardless libr time
appreci best-in-class product pipelin continu build
launch approach also convict non-intens type adopt
question remain top pick
revenu y/i came consensu
forecast expect beat link clearli well
expect rel model everi revenu line exceed expect new
patient sensor util us ou broad base blow-out quarter page
detail
gross margin came forecast
consensu howev result larg line manag guidanc
q/q increas oper margin forecast
consensu oper profit exceed forecast
revenu guidanc rais midpoint gross
margin guidanc reduc entir due manufactur
constraint fulli address earli howev oper margin
guidanc increas
revenu guidanc impli q/q revenu growth vs even
high end would lowest sequenti growth rate histori
model manag cite multipl factor drive guidanc primari driver
manufactur constraint ultim long manufactur issu
intensifi expect exceed high end guidanc rang
continu add new patient impress clip penetr across
compani core market still low see reason momentum slow
link libr improv competit posit expect featur
better perform high/low alert still expect accurate/reli
product market abbott also talk significantli increas advertis
presenc music ear increas awar
overal cgm adopt help ever sinc libr first launch
expect ultim exceed consensu expect ep
expect also seemingli far low increas revenu ep forecast
respect significantli consensu expect
despit forecast assum new patient add declin vs instal base
growth moder significantli could upsid
continu page
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model competit potenti long-term price headwind
exist howev best pipelin industri expect remain clear
cgm market leader forese futur wherev market goe
us type cgm penetr continu
rapidli increas toward standard
growth forese futur
cgm penetr continu rapidli
increas toward standard care us
cgm begin adopt
revenu growth sustain pace
beyond
type penetr come faster
cgm penetr slow fail progress
toward standard care
price deterior faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet use healthcar
provid hospit treatment patient without diabet dexcom
flagship offer today dexcom mobil patient diabet detect
trend track glucos pattern fda approv pediatr patient adult
move forward compani focus continu drive advanc cgm
technolog focus accuraci comfort connect longer term dexcom
goal replac tradit blood glucos monitor technolog
even approach annual revenu remain long runway
us type us intens manag type far lower ou continu
convict adopt amongst non-intens type patient popul
question massiv fast grow market best
product pipelin industri launch huge catalyst significantli rais
near long term estim accordingli rais dcf-deriv price target
remain top pick
compani report thomson eikon cowen compani
cowen vs consensu mm except re-affirmed re-affirmed oper non-gaap revenu metric mm except statement mm except per count durabl revenu came expect grow y/i vs expect slight declin receiv transmitt revenu exceed expect driven higher expect new patient add estim overal transmitt util new patient add like exceed expect sensor revenu came forecast rel model upsid driven new patient upsid overal util upsid fantast quarter util seemingli quit strong vs recent ep came significantli ahead expect strong top bottom revenu came consensu expect expect least beat well expect essenti everi line item exceed expect new patient add sensor util us ou etc fantast quarter guidanc suggest momentum continu gross margin came forecast consensu manag guid investor expect q/q increas ultim pretti close quarter play came forecast despit signific revenu beat sg forecast despit signific revenu beat oper margin came expect consensu blow-out top bottom beat cowen
compani report thomson eikon cowen compani
mm except per share day profit day gener oper non-gaap day day less long termnet earn per consensu estim mm except per share gross op cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
